C. Williams

发表

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.

A. Shaw, S. Ou, T. Mok, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study.

A. Shaw, S. Peters, D. Camidge, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.